ClinicalTrials.gg
Not yet recruitingNCT07560722Updated May 1, 2026

The Effect of a Single Intravenous Injection of Esketamine During Cesarean Section on Postoperative Pruritus in Patients With Intrahepatic Cholestasis of Pregnancy

An interventional study of Normal Saline (0.9% NaCl) and Esketamine 0.3mg/kg in Intrahepatic Cholestasis of Pregnancy, sponsored by Tianjin Medical University General Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Tianjin Medical University General Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

To explore the effect of a single intravenous injection of esketamine during cesarean section on postoperative pruritus in patients with intrahepatic cholestasis of pregnancy.

Read the detailed description

Intrahepatic cholestasis of pregnancy (ICP) is an important obstetric complication that occurs in the middle and late stages of pregnancy, characterized mainly by pruritus and elevated serum total bile acid (TBA) levels.

Pruritus usually begins on the palms and soles of the feet and can gradually spread. It typically shows a 'lighter during the day and heavier at night' pattern, severely affecting the patient's quality of life. It can also lead to physical and psychological disorders, and even cause mental abnormalities and self-harming behaviors in patients.

Esketamine is the right-handed isomer of ketamine and is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It has the effects of rapid pain relief, rapid antidepressant action, sedation, and improvement of sleep. Relevant studies have shown that the NMDA receptor may play an important role in the transmission of non-histaminergic itching. Eslicarbazepine acetate, as a highly selective NMDA receptor antagonist, may alleviate the transmission and propagation of itching. However, there are no reports on whether a single intravenous injection of esketamine can alleviate the pruritus symptoms of patients with pregnancy-induced intrahepatic cholestasis. This experiment aims to investigate the effect of a single intravenous injection of esketamine during cesarean section on postoperative pruritus in patients with pregnancy-induced intrahepatic cholestasis.

02

Conditions studied

  • Intrahepatic Cholestasis of Pregnancy

Keywords

  • esketamine
  • pruritus
03

In context

Intrahepatic Cholestasis of Pregnancy

26 studies on the registry are indexed under Intrahepatic Cholestasis of Pregnancy; 10 are open to participants now.

Browse Intrahepatic Cholestasis of Pregnancy studies →

Lead sponsor

Tianjin Medical University General Hospital is the lead sponsor of 75 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 - 40 years old; Gestational age: ≥ 35 weeks; Singleton pregnancy.
  2. Clear consciousness, able to cooperate with NRS scoring, laboratory tests and follow-up.
  3. Meet the diagnostic criteria of the "Clinical Diagnosis, Treatment and Management Guidelines for Intrahepatic Cholestasis of Pregnancy (2024 Edition)" : fasting serum TBA≥10 μmol/L or postprandial serum TBA≥19 μmol/L.
  4. Reporting pruritus NRS ≥ 4 points twice within one week.
  5. Planned to undergo cesarean section under intraspinal anesthesia.
  6. : I - III grade.

Exclusion criteria

Exclusion Criteria:

  1. Those who are known to be allergic to the drug components or have an allergic constitution.
  2. Related to the safe use of esketamine: history of mental illness; uncontrolled hypertension; uncontrolled hyperthyroidism; increased intracranial pressure, increased intraocular pressure; long-term alcohol consumption or drug abuse history.
  3. Those with severe organic diseases and liver diseases.
  4. Those with malignant tumors.
  5. Other pruritic diseases: uremic pruritus, true erythrocytosis, cutaneous T-cell lymphoma, eosinophilia, drug rash and drug-induced pruritus, and other pruritic diseases that are easily confused, such as atopic dermatitis, pemphigus, scabies, parasitic delusionism, artificial dermatitis, etc.
  6. Eclampsia and pre-eclampsia, HELLP syndrome; fetal developmental abnormalities, multiple pregnancies.
  7. as grade IV.
  8. Those with poor compliance and unable to complete the trial according to the research protocol.
  9. Those who have participated in other drug clinical trials within the past 4 weeks.
  10. Due to any reason, the researchers consider that there is any situation that is not suitable for inclusion.

    -

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group of parturients with ICP and pruritus received normal saline

    The equal volume of normal saline was injected intravenously after fetal delivery during the operation

    Drug: Normal Saline (0.9% NaCl)

  • Active comparator
    Group of parturients with ICP and pruritus received esketamine 0.3mg/kg

    Esketamine 0.3mg/kg was injected intravenously after fetal delivery during the operation

    Drug: Esketamine 0.3mg/kg

Interventions

  • DrugNormal Saline (0.9% NaCl)

    The same volume of normal saline was injected after fetal delivery during the operation

  • DrugEsketamine 0.3mg/kg

    Drug page: Esketamine

    Esketamine 0.3mg/kg was given intravenously after fetal delivery during the operation

06

What researchers measure

Primary outcomes

  1. NRS pruritus score at 24 hours after surgery

    The patient evaluated the intensity of pruritus with 11 numbers ranging from 0 to 10, and the higher the number, the more severe the condition. The higher the number, the more severe the itching. 0: No sensation. 1-3: Mild itching. 4-6: Moderate itching. 7-9: Severe itching. 10: Extremely severe itching.

    Time frame: 24 hours after the surgery

Secondary outcomes

  1. 5-D itch scale at 72 hours after surgery

    The duration, severity, outcome trend, life impairment, and pruritus site (5-D) were used to evaluate the patient's pruritus. Each dimension was scored from 1 to 5, with a total score ranging from 5 to 25. The higher the score, the more severe the itching.

    Time frame: 72 hours after surgery

  2. NRS pruritus score at 6 hours、12 hours、48 hours、72h ours and the seventh day after surgery

    The patient evaluated the intensity of pruritus with 11 numbers ranging from 0 to 10, and the higher the number, the more severe the condition. The higher the number, the more severe the itching. 0: No sensation. 1-3: Mild itching. 4-6: Moderate itching. 7-9: Severe itching. 10: Extremely severe itching.

    Time frame: 6 hours、12 hours、48 hours、72 hours and the seventh day after surgery

  3. The incidence of pruritus on the 24 hours after surgery

    The NRS pruritus score was completed by the patient 24 hours after the operation. The investigators recorded this score as a statistical indicator.

    Time frame: 24 hours after surgery

  4. Total bile acid at 24 hours after surgery

    The patient's fasting total bile acid level was checked the day before the operation. The investigators rechecked the fasting total bile acid levels 24 hours after the patient's surgery to assess the changes in total bile acid.

    Time frame: 24 hours after surgery

  5. Pain Score (NRS)

    The pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10 = greatest imaginable pain.

    Time frame: 6 hours, 12 hours, 24 hours, 48 hours, 72 hours after the surgery

  6. The incidence of postoperative sleep disturbance on the first、second and third postoperative nights

    The patient completed the Sleep Quality Scale (AIS,Athens Insomnia Scale) one day before the surgery. There are a total of 8 items in the AIS, with the score ranging from 0 to 24. A total score of 6 or above indicates a diagnosis of insomnia. We asked the patients to fill out this questionnaire after the first, second and third postoperative nights to evaluate the changes in sleep quality. The investigators recorded AIS scores as statistical indicators.

    Time frame: the first、second and third nights after surgery

  7. Postoperative anxiety

    The patient completed the Self-Rating Anxiety Scale (SAS, Self-Rating Anxiety Scale) one day before the surgery. The SAS consists of 20 items. Among them, 15 items are positive ratings (such as "I feel more nervous and anxious than usual"), and 5 items are negative ratings (such as "I feel everything is fine", which are the reverse items numbered 5, 9, 13, 17, and 19). The content covers subjective feelings of anxiety and various physical symptoms. The investigators asked the patient to fill out this questionnaire again 72 hours after the surgery to assess the changes in anxiety.

    Time frame: 72 hours after the surgery

  8. Postoperative depression

    The patient completed the Edinburgh Depression Scale (EPDS) one day before the surgery. The EPDS consists of 10 items, covering aspects such as mood, anxiety, and self-blame. Scores range from 0 to 9: within the normal range, no special intervention is required; 10-12: borderline range, suggesting a need for follow-up observation; 13-30: screening positive, indicating possible postpartum depression, and further assessment is necessary. The investigators asked the patient to fill out this questionnaire again at the seventy-second hour after the surgery to assess the changes in depression.

    Time frame: 72 hours after the surgery

  9. Key time points of the surgery

    1. Duration of anesthesia (minutes) 2. Duration of surgery (minutes) 3. The time of fetal delivery(minutes)

    Time frame: Perioperative period

  10. Intraoperative average blood pressure(mmHg)

    Time frame: Perioperative period

  11. Intraoperative average heart rate(times per minute)

    Time frame: Perioperative period

  12. Intraoperative average blood oxygen saturation(%)

    Time frame: Perioperative period

  13. Intraoperative adverse reactions ( elevated blood pressure, tachycardia, hallucinations, nausea, vomiting, etc.)

    Time frame: Perioperative period

  14. Adverse event

    All kinds of adverse events( nausea, vomiting, headache,etc) occurred in patients were recorded.

    Time frame: Within 72 hours after the surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560722
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Guolin Wang (Professor, Tianjin Medical University General Hospital) — Principal investigator
First posted
May 1, 2026
Start date
May 5, 2026 (estimated)
Primary completion
May 5, 2027 (estimated)
Completion
Aug 11, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Guolin Wang
Contact
wangguolinghad@hotmail.com
+8615822855556
Guolin Wang
study director · Tianjin Medical University General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion